X-linked hypophosphataemia (XLH) is the most common inherited form of hypophosphataemic rickets, a diverse group of inherited disorders involving impaired bone mineralisation due to hypophosphataemia, which leads to bone weakness and deformities, bowed limbs, reduced growth, bone pain and associated disorders. Even though current therapy can improve the signs of rickets and biochemical parameters, the disease constitutes a serious burden and negatively affects the quality of life of the patients, causing serious morbidity at adult age.
This report provides the current prevalent population for XLH across 20 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Norway, Austria, Russia, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, some features of XLH patients, as well as the main comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of XLH include:
- Insufficiency fractures
- Dental disease
- Tertiary hyperparathyroidism (treatment-related)
- Hearing impairment
- Optic atrophy
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
- Ability to quantify patient populations in global XLH market to target the development of future products, pricing strategies and launch plans.
- Further insight into the prevalence of the subdivided types of XLH and identification of patient segments with high potential.
- Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
- Better understanding of the impact of specific co-morbid conditions on the prevalent population of XLH patients.
- Identification of XLH patient sub-populations that require treatment.
- Better understanding of the specific markets that have the largest number of XLH patients.